tbuckley/cabot-search huggingface dataset:
Epidemia de sarampión en Suiza en 1997: consecuencias para la eliminación del sarampión en el año 2007
Authors: W J Paget, H Zimmermann, H Vorkauf
Journal: Eurosurveillance (2000)

Desde junio de 1986, los casos clinicos de sarampion son declarados a Sentinella, la Red de Vigilancia Centinela de Suiza (SSSN) (1), y, desde enero de 1988, los casos de infeccion se notifican a traves del sistema nacional de declaracion por laboratorio. Estos dos sistemas de vigilancia forman una de las principales herramientas para evaluar las actividades de inmunizacion contra el sarampion, la parotiditis y la rubeola (SPR) realizadas en Suiza. La vacunacion contra el sarampion se recomienda desde 1976 y, en 1987, el Consejo Asesor Suizo en Materia de Inmunizacion y la Oficina Federal Suiza de Salud Publica (SFOPH) lanzaron una campana de vacunacion SPR de ambito nacional. Desde 1996, se recomienda la administracion a todos los ninos de dos dosis de SPR: a los 15 meses y antes de la entrada en la escuela (4 a 7 anos).
Chronic Traumatic Encephalopathy in Football Players—Reply
Authors: Ann C. McKee, Jesse Mez, Bobak Abdolmohammadi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Uterine Artery Flow and Offspring Growth in Long-Evans Rats following Maternal Exposure to Ozone during Implantation
Authors: Colette N. Miller, Janice A. Dye, Allen D. Ledbetter, Mette C. Schladweiler, Judy H. Richards, Samantha J. Snow, Charles E. Wood, Andres R. Henriquez, Leslie C. Thompson, Aimen K. Farraj, Mehdi S. Hazari, Urmila P. Kodavanti
Journal: Environmental Health Perspectives (2017)

Background: Epidemiological studies suggest that increased ozone exposure during gestation may compromise fetal growth. In particular, the implantation stage of pregnancy is considered a key window of susceptibility for this outcome. Objectives: The main goals of this study were to investigate the effects of short-term ozone inhalation during implantation on fetal growth outcomes and to explore the potential for alterations in uterine arterial flow as a contributing mechanism. Methods: Pregnant Long-Evans rats were exposed to filtered air, 0.4 ppm ozone, or 0.8 ppm ozone for 4 h/d during implantation, on gestation days (GD) 5 and 6. Tail cuff blood pressure and uterine artery Doppler ultrasound were measured on GD 15, 19, and 21. To assess whether peri-implantation ozone exposure resulted in sustained pulmonary or systemic health effects, bronchoalveolar lavage fluid, serum metabolic and inflammatory end points, and kidney histopathology were evaluated in dams at GD 21. Growth parameters assessed in GD 21 offspring included fetal weight, length, and body composition. Results: Measures of maternal uterine arterial flow, including resistance index and mean velocity, indicated that resistance increased between GD 15 and GD 21 in 0.8 ppm dams but decreased in controls, although absolute values were similar in both groups on GD 21. Ozone-exposed dams also had lower serum glucose and higher free fatty acid concentrations than controls on GD 21. On GD 21, both male and female offspring had lower body weight than controls, and pooled subsets of 3 male and 3 female fetuses from litters exposed to 0.8 ppm ozone had lower lean mass and fat mass than pooled control offspring. Conclusions: Findings from our experimental model suggest that the offspring of dams exposed to ozone during implantation had reduced growth compared with controls, possibly as a consequence of ozone-induced vascular dysfunction. https://doi.org/10.1289/EHP2019
Vigilância serológica da rubéola na Europa: Rede Sero-Epidemiológica Europeia (ESEN2)
Authors: A Nardone, E Miller
Journal: Eurosurveillance (2004)

A vigilância serologica constitui um importante recurso para avaliar programas de vacinacao, especialmente para doencas como a rubeola, onde um programa subideal pode conduzir a um aumento da morbilidade. E necessaria uma politica de vacinacao coordenada na Europa, e o objectivo da Rede Sero-Epidemiologica Europeia (ESEN2) consiste em padronizar a vigilância serologica em 22 paises para oito doencas, incluindo a rubeola.
NRF2 CONTROLS SYSTEMIC IRON HOMEOSTASIS VIA BMP6 AND HEPCIDIN AND ALLEVIATES HEMOCHROMATOSIS
Authors: P J Lim, T L Duarte, Pasricha S-R., A E Armitage, A G Santos, A Morovat, E Soilleux, Wang C-Y., J L Babitt, G Porto, H Drakesmith
Journal: American Journal of Hematology (2017)
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice
Authors: Alan S. Go, Daniel E. Singer, Sengwee Toh, T. Craig Cheetham, Marsha E. Reichman, David J. Graham, Mary Ross Southworth, Rongmei Zhang, Rima Izem, Margie R. Goulding, Monika Houstoun, Katrina Mott, Sue Hee Sung, Joshua J. Gagne
Journal: Annals of Internal Medicine (2017)

This article has been corrected. The original version (PDF) is appended to this article as a Supplement. Background: Dabigatran (150 mg twice daily) has been associated with lower rates of stroke than warfarin in trials of atrial fibrillation, but large-scale evaluations in clinical practice are limited. Objective: To compare incidence of stroke, bleeding, and myocardial infarction in patients receiving dabigatran versus warfarin in practice. Design: Retrospective cohort. Setting: National U.S. Food and Drug Administration Sentinel network. Patients: Adults with atrial fibrillation initiating dabigatran or warfarin therapy between November 2010 and May 2014. Measurements: Ischemic stroke, intracranial hemorrhage, extracranial bleeding, and myocardial infarction identified from hospital claims among propensity score–matched patients starting treatment with dabigatran or warfarin. Results: Among 25 289 patients starting dabigatran therapy and 25 289 propensity score–matched patients starting warfarin therapy, those receiving dabigatran did not have significantly different rates of ischemic stroke (0.80 vs. 0.94 events per 100 person-years; hazard ratio [HR], 0.92 [95% CI, 0.65 to 1.28]) or extracranial hemorrhage (2.12 vs. 2.63 events per 100 person-years; HR, 0.89 [CI, 0.72 to 1.09]) but were less likely to have intracranial bleeding (0.39 vs. 0.77 events per 100 person-years; HR, 0.51 [CI, 0.33 to 0.79]) and more likely to have myocardial infarction (0.77 vs. 0.43 events per 100 person-years; HR, 1.88 [CI, 1.22 to 2.90]). However, the strength and significance of the association between dabigatran use and myocardial infarction varied in sensitivity analyses and by exposure definition (HR range, 1.13 [CI, 0.78 to 1.64] to 1.43 [CI, 0.99 to 2.08]). Older patients and those with kidney disease had higher gastrointestinal bleeding rates with dabigatran. Limitation: Inability to examine outcomes by dabigatran dose (unacceptable covariate balance between matched patients) or quality of warfarin anticoagulation (few patients receiving warfarin had available international normalized ratio values). Conclusion: In matched adults with atrial fibrillation treated in practice, the incidences of stroke and bleeding with dabigatran versus warfarin were consistent with those seen in trials. The possible relationship between dabigatran and myocardial infarction warrants further investigation. Primary Funding Source: U.S. Food and Drug Administration.
Moldable Hyaluronan Hydrogel Enabled by Dynamic Metal–Bisphosphonate Coordination Chemistry for Wound Healing
Authors: Liyang Shi, Yannan Zhao, Qifan Xie, Caixia Fan, Jöns Hilborn, Jianwu Dai, Dmitri. A. Ossipov
Journal: Advanced Healthcare Materials (2017)

Biomaterial-based regenerative approaches would allow for cost-effective off-the-shelf solution for the treatment of wounds. Hyaluronan (HA)-based hydrogel is one attractive biomaterial candidate because it is involved in natural healing processes, including inflammation, granulation, and reepithelialization. Herein, dynamic metal-ligand coordination bonds are used to fabricate moldable supramolecular HA hydrogels with self-healing properties. To achieve reversible crosslinking of HA chains, the biopolymer is modified with pendant bisphosphonate (BP) ligands using carbodiimide coupling and chemoselective "click" reactions. Hydrogel is formed immediately after simple addition of silver (Ag+ ) ions to the solution of HA containing BP groups (HA-BP). Compared with previous HA-based wound healing hydrogels, the HA-BP·Ag+ hydrogel is highly suitable for clinical use as it can fill irregularly shaped wound defects without the need for premolding. The HA-BP·Ag+ hydrogel shows antimicrobial properties to both Gram-positive and Gram-negative bacterial strains, enabling prevention of infections in wound care. In vivo evaluation using a rat full-thickness skin wound model shows significantly lower wound remaining rate and a thicker layer of regenerated epidermis as compared with the group left without treatment. The presented moldable and self-healing supramolecular HA hydrogel with "ready-to-use" properties possesses a great potential for regenerative wound treatment.
Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding
Authors: F. Yan, P.F. Thall, K.H. Lu, M.R. Gilbert, Y. Yuan
Journal: Annals of Oncology (2017)

BackgroundConventional phase I algorithms for finding a phase-2 recommended dose (P2RD) based on toxicity alone is problematic because the maximum tolerated dose (MTD) is not necessarily the optimal dose with the most desirable risk–benefit trade-off. Moreover, the increasingly common practice of treating an expansion cohort at a chosen MTD has undesirable consequences that may not be obvious.Patients and methodsWe review the phase I–II paradigm and the EffTox design, which utilizes both efficacy and toxicity to choose optimal doses for successive patient cohorts and find the optimal P2RD. We conduct a computer simulation study to compare the performance of the EffTox design with the traditional 3 + 3 design and the continuous reassessment method.ResultsBy accounting for the risk–benefit trade-off, the EffTox phase I–II design overcomes the limitations of conventional toxicity-based phase I designs. Numerical simulations show that the EffTox design has higher probabilities of identifying the optimal dose and treats more patients at the optimal dose.ConclusionsPhase I–II designs, such as the EffTox design, provide a coherent and efficient approach to finding the optimal P2RD by explicitly accounting for risk–benefit trade-offs underlying medical decisions.
Abstract 16584: Bone Morphogenetic Protein 1/Tolloid-Like Metalloproteinase (BMP-1/TLD) is Increased in Heart Failure and Regulates MMP12 and TIMP1 Levels in Cardiomyocytes
Authors: Estibaliz Castillero, Ruiping Ji, Nathaniel Kheysin, Sanatkumar Patel, Diana Leung, Sheetal Hegde, Joo-Eun S Park, Samantha Stein, Carlos Cuenca, Hirokazu Akashi, Catherine Wang, Ziad A Ali, Paolo C Colombo, H Lee Sweeney, Paul Christian Schulze, Isaac George
Journal: Circulation (2016)

Introduction: Myostatin (MSTN) is involved in cardiac remodeling and fibrosis in heart failure (HF), and becomes activated after cleavage by bone morphogenic-1/tolloid (BMP1/TLD) proteinase. We hav...
Nutritional and functional status impairments to predict early death in elderly patients with advanced non-small-cell lung cancer (NSCLC).
Authors: Andrea Luciani, Carmela Careri, Barbara Bocci, Martina Violati, Alessandro Guidi, Miriam Blasi, Veronica Bordin, Sarah Caldiera, Sabrina Zonato, Daris Ferrari
Journal: Journal of Clinical Oncology (2017)

e20600 Background: Early death for some patients can be explained by direct effect of tumor or can be secondary to cancer treatment.As for many patients it is not fully predictable, the factors influencing and determining early death in older individuals receiving chemotherapy for advanced NSCLC were analyzed. Methods: Advanced NSCLC patients, &gt; 70 years, ECOG performance status 0-1, treatment naïve, stage IIIB and IV, EGFR and ALK negative, were eligible. Geriatric assessment was performed at baseline and included: Performance status, ADLs, IADLs, CIRSG score and index, Mini Nutritional Assessment (MNA), Mini Mental State Evaluation (MMSE), educational and social status assessment, Geriatric Depression Scale (GDS).All patients, according to their classification in frail, vulnerable or fit, received best supportive care, monotherapy or doublet chemotherapy.For all patients data on number of cycles, response, discontinuation of treatment, dose reductions, grade 3/4 hematological and non-hematological toxicity were recorded. Patients who died within 90 days of diagnosis were considered.A descriptive statistic was calculated and a logistic regression analysis with the assessment of factors and covariates influencing early death events was performed. Results: From June 2010 to March 2016, 204 patients were assigned to platinum-based doublet (n = 73) or single-agent chemotherapy (n = 131).Median age was 75, 72% were males, 52% had non-squamous histology. Median number of cycles was 4, and was 3 for comorbidities. IADLs were impaired in 42%, ADLs in 6%,MNA in 15% and MMSE 10% of patients.Sixty-eight percent of patients were dead at the time of the analysis; 24% (49/204) had partial response, 25% (51/204) had stable disease and 51% (104/204) had progressive disease.At multivariate logistic model IADLs (p 0.001, OR 1.4 95%CI 0.4-1.6),MNA (p 0.001, OR 1.35 CI 0.1-1.35) and polypharmacy (p 0.008, OR 1.2 CI 1-1.4) were significantly associated with the occurrence of early death. Conclusions: The identification and management of patients with nutritional and functional impairments could help oncologists to reduce the risk of early death during chemotherapy for advanced NSCLC.
Patient‐reported outcomes in cirrhosis: A scoping review of the literature
Authors: Elliot B. Tapper, Fasiha Kanwal, Sumeet K. Asrani, Chanda Ho, Nadia Ovchinsky, John Poterucha, Avegail Flores, Judith E. Smith, Victor Ankoma‐Sey, Bruce Luxon, Michael L. Volk
Journal: Hepatology (2017)

Patients with cirrhosis seek improvement in their symptoms, functioning, quality of life, and satisfaction with the care they receive. However, these patient-reported outcomes (PROs) are not routinely measured for clinical care, research, or quality improvement. The members of the American Association for the Study of Liver Diseases Practice Metrics Committee, charged with developing quality indicators for clinical practice, performed a scoping review of PROs in cirrhosis. The aim is to synthesize a comprehensive set of PROs for inclusion into a standard patient-centered outcome set. We searched Medline, Embase, the Cumulative Index to Nursing and Allied Health Literature, PsycINFO, and the Cochrane Trial Library since inception, with final searches run between April 20 and June 1, 2017. Studies were included if they reported the construction and/or validation of a PRO instrument for patients with cirrhosis or if they assessed the clinical (case-mix) variables determining responses to established PRO scales. Eleven studies were selected that yielded 259 items specific to patients with cirrhosis. After removing duplicates, 152 unique items were isolated. These items were consolidated into seven domains: physical symptoms, physical function, mental health, general function, cognition, social life, and satisfaction with care. The seven domains included 52 subdomains (e.g., physical domain, abdominal pain subdomain). Twelve variables were identified that independently modified established PRO scales. These included clinical factors (severity of liver disease and its complications, medication burden, and comorbidities), specific PROs (cramps, pruritis), and surrogate outcome measures (falls, hospitalization). This scoping review identified and categorized a large existing set of PRO concepts that matter to patients with cirrhosis; these outcomes may now be translated into usable measures both for the assessment of the quality of cirrhosis care in clinical practice and to perform research from the patient's perspective. (Hepatology 2018;67:2375-2383).
Hypoxia‐inducible factor‐1 (HIF‐1) inhibitors from the last decade (2007 to 2016): A “structure–activity relationship” perspective
Authors: Deepak Bhattarai, Xuezhen Xu, Kyeong Lee
Journal: Medicinal Research Reviews (2017)

Abstract Tumor hypoxia is a common feature in most solid tumors and is associated with overexpression of the hypoxia response pathway. Overexpression of the hypoxia‐inducible factor (HIF‐1) protein leads to angiogenesis, metastasis, apoptosis resistance, and many other pro‐tumorigenic responses in cancer development. HIF‐1 is a promising target in cancer drug development to increase the patient's response to chemotherapy and radiotherapy as well as the survival rate of cancer patients. Since up to 1% of genes are hypoxia‐sensitive, a target‐specific HIF‐1 inhibitor may be a better clinical candidate in cancer drug discovery. Though no HIF‐1 inhibitor is clinically available to date, a lot of effort has been applied during the last decade in search of potent HIF‐1 inhibitors. In this review, we will summarize the structure–activity relationship of ten different chemotypes reported to be HIF‐1 inhibitors in the last decade (2007–2016), their mechanisms of action for HIF‐1 inhibition, progress in the way of target‐specific inhibitors, and problems associated with current inhibitors. It is anticipated that the results of these research on the medicinal chemistry of HIF‐1 inhibitors will provide decent information in the design and development of future inhibitors.
Guided early deescalation of antiplatelet treatment was noninferior to usual prasugrel care in PCI-treated ACS
Authors: Eric R. Bates
Journal: Annals of Internal Medicine (2017)

Source Citation Sibbing D, Aradi D, Jacobshagen C, et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747-57. 28855078
Comparison of epidemiological characteristics and medical utilization of asthma-predominant ACO(Asthma COPD Overlap) and COPD
Authors: Young Joo Cho, Min-Hye Kim, Jin Hwa Lee, Chin Kook Lee, Kyungjoo Kim, Kwang Ha Yoo, Ki-Suck Jung
Journal: Journal of Allergy and Clinical Immunology (2018)
An algorithm for the classification of mRNA patterns in eosinophilic esophagitis: Integration of machine learning
Authors: Benjamin F. Sallis, Lena Erkert, Sherezade Moñino-Romero, Utkucan Acar, Rina Wu, Liza Konnikova, Willem S. Lexmond, Matthew J. Hamilton, W. Augustine Dunn, Zsolt Szepfalusi, Jon A. Vanderhoof, Scott B. Snapper, Jerrold R. Turner, Jeffrey D. Goldsmith, Lisa A. Spencer, Samuel Nurko, Edda Fiebiger
Journal: Journal of Allergy and Clinical Immunology (2017)
Clinical implications and considerations for evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines
Authors: Lora J. H. Bean, Madhuri R. Hegde
Journal: Genome Medicine (2017)

Clinical genetics laboratories have recently adopted guidelines for the interpretation of sequence variants set by the American College of Medical Genetics (ACMG) and Association for Molecular Pathology (AMP). The use of in silico algorithms to predict whether amino acid substitutions result in human disease is inconsistent across clinical laboratories. The clinical genetics community must carefully consider how in silico predictions can be incorporated into variant interpretation in clinical practice.Please see related Research article: https://doi.org/10.1186/s13059-017-1353-5.
Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: paradoxical effects of zolpidem
Authors: Jayne C. Carberry, Lauren P. Fisher, Ronald R. Grunstein, Simon C. Gandevia, David K. McKenzie, Jane E. Butler, Danny J. Eckert
Journal: European Respiratory Journal (2017)

Hypnotics are contraindicated in obstructive sleep apnoea (OSA) because of concerns of pharyngeal muscle relaxation and delayed arousal worsening hypoxaemia. However, human data are lacking. This study aimed to determine the effects of three common hypnotics on the respiratory arousal threshold, genioglossus muscle responsiveness and upper airway collapsibility during sleep. 21 individuals with and without OSA (18–65 years) completed 84 detailed sleep studies after receiving temazepam (10 mg), zolpidem (10 mg), zopiclone (7.5 mg) and placebo on four occasions in a randomised, double-blind, placebo-controlled, crossover trial (ACTRN12612001004853). The arousal threshold increased with zolpidem and zopiclone versus placebo (mean± sd −18.3±10 and −19.1±9 versus −14.6±7 cmH 2 O; p=0.02 and p&lt;0.001) but not with temazepam (−16.8±9 cmH 2 O; p=0.17). Genioglossus muscle activity during stable non-REM sleep and responsiveness during airway narrowing was not different with temazepam and zopiclone versus placebo but, paradoxically, zolpidem increased median muscle responsiveness three-fold during airway narrowing (median −0.15 (interquartile range −1.01 to −0.04) versus −0.05 (−0.29 to −0.03)% maximum EMG per cmH 2 O epiglottic pressure; p=0.03). The upper airway critical closing pressure did not change with any of the hypnotics. These doses of common hypnotics have differential effects on the respiratory arousal threshold but do not reduce upper airway muscle activity or alter airway collapsibility during sleep. Rather, muscle activity increases during airway narrowing with zolpidem.